
Please try another search
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company’s product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Name | Age | Since | Title |
---|---|---|---|
Derek LeRoith | - | - | Member of Scientific Advisory Board |
Jeremy Pettus | - | - | Member of Scientific Advisory Board |
Michael E. Castagna | 44 | 2016 | CEO & Director |
Anne L. Peters | - | - | Member of Scientific Advisory Board |
John Anderson | - | - | Member of Scientific Advisory Board |
John B. Buse | - | - | Chair of Scientific Advisory Board |
Satish K. Garg | - | - | Member of Scientific Advisory Board |
Kathleen Dungan | - | - | Member of Scientific Advisory Board |
Eda Cengiz | - | - | Member of Scientific Advisory Board |
James S. Shannon | 66 | 2015 | Independent Chairman |
Michael A. Friedman | 80 | 2003 | Independent Director |
Ronald J. Consiglio | 80 | 2003 | Independent Director |
Jennifer Lisa Grancio | 52 | 2020 | Independent Director |
Anthony C. Hooper | 69 | 2020 | Independent Director |
Christine Ann M. Mundkur | 55 | 2018 | Independent Director |
Davida F. Kruger | - | 2021 | Member of Scientific Advisory Board |
David Maahs | - | 2021 | Member of Scientific Advisory Board |
Sabrina A. Kay | 61 | 2020 | Independent Director |
Janet B. McGill | - | 2021 | Member of Scientific Advisory Board |
Anders L. Carlson | - | 2021 | Member of Scientific Advisory Board |
Thomas C. Blevins | - | 2021 | Member of Scientific Advisory Board |
Bruce W. Bode | - | 2021 | Member of Scientific Advisory Board |
Scott W. Lee | - | 2021 | Member of Scientific Advisory Board |
Kashif Latif | - | 2021 | Member of Scientific Advisory Board |
Philip Levin | - | 2021 | Member of Scientific Advisory Board |
Steven B. Binder | 62 | 2017 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review